Search results for "Cyst"

showing 10 items of 1960 documents

The spectrum of androgen excess disorders.

2006

A better understanding of the different phenotypes and of their endocrine and metabolic characteristics permits investigators to distinguish three main androgen excess disorders: classic polycystic ovary syndrome (PCOS), mild ovulatory PCOS, and idiopathic hyperandrogenism. These androgenic phenotypes differ more for the severity of the endocrine and metabolic alteration than for the etiopathogenetic mechanisms. The appearance of a particular androgenic phenotype is determined by a sum of genetic and environmental factors, but mostly by body weight.

Malemedicine.medical_specialtymedicine.drug_classBiologyAndrogen ExcessDiagnosis DifferentialInsulin resistancePolycystic ovary syndrome hyperandrogenism androgen excess insulin resistance idiopathic hirsutismInternal medicinemedicineEndocrine systemHumanshirsutismHyperandrogenismObstetrics and Gynecologymedicine.diseaseAndrogenPhenotypePolycystic ovaryEndocrinologyReproductive MedicinePractice Guidelines as TopicAndrogensFemaleHyperandrogenismPolycystic Ovary SyndromeFertility and sterility
researchProduct

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective Internationa…

2017

IF 3.156; International audience; Background: Radical cystectomy (RC) and radiochemotherapy (RCT) are curative options for muscle-invasive bladder cancer (MIBC). Optimal treatment strategy remains unclear in elderly patients.Material and methods: Patients aged 80 years old and above with T2-T4aN0-2M0-Mx MIBC were identified in the Retrospective International Study of Cancers of the Urothelial Tract (RISC) database. Patients treated with RC were compared with those treated with RCT. The impact of surgery on overall survival (OS) was assessed using a Cox proportional hazard model. Progression included locoregional and metastatic relapse and was considered a time-dependent variable.Results: Be…

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyUrology[SDV.CAN]Life Sciences [q-bio]/CancerKaplan-Meier EstimateCystectomyBladder preservationDisease-Free Survivallaw.inventionCystectomy03 medical and health sciences0302 clinical medicineRandomized controlled triallawCarcinomamedicineHumansRadiology Nuclear Medicine and imagingProportional Hazards ModelsRetrospective StudiesAged 80 and overCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelMuscle invasiveRetrospective cohort studyHematologyGeneral MedicineChemoradiotherapymedicine.disease3. Good healthSurgeryTreatment OutcomeOncologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisFemalebusinessActa oncologica (Stockholm, Sweden)
researchProduct

A 9-Year Retained T-Tube Fragment Encased within a Stone as a Rare Cause of Jaundice

2008

Biliary diseases such as cholangitis may cause jaundice and liver damage. Here, we report on an unusual cause of jaundice in an 84-year-old man 9 years after cholecystectomy. Ultrasound analysis revealed unclear extrahepatic cholestasis and subsequent ERCP showed a large biliary stone sourrounding a T-tube fragment that had remained in the common bile duct for more than 9 years after surgery. The tip of the drainage and the stone could be successfully removed using Dormia baskets. This case suggests that plastic material accidentally left in the common bile duct favours the development of large biliary casts when present over long periods of time.

Malemedicine.medical_specialtymedicine.medical_treatmentBile Duct DiseasesExtrahepatic CholestasisGastroenterologyInternal medicinemedicineHumansCholecystectomyLiver damageAged 80 and overCommon bile ductbusiness.industryForeign-Body ReactionGastroenterologyJaundiceSurgeryJaundice ObstructiveTreatment OutcomeBiliary stonemedicine.anatomical_structureStentsCholecystectomymedicine.symptombusinessZeitschrift für Gastroenterologie
researchProduct

The significance of premature luteinization in an oocyte-donation programme

2006

BACKGROUND: Several evidences indicate that premature luteinization (PL) may affect IVF outcome. The primary end-point of the present study was to verify the effect of PL on the pregnancy rate (PR) of our oocytedonation programme. METHODS: PL was defined as serum progesterone ³1.2 ng/ml on the day of HCG. We analysed retrospectively 240 oocyte-donation cycles in which 120 women donated twice, with PL in the first donation cycle and no PL in the following one, acting as its own control. Recipients (n = 240) were divided in two groups according to the presence of PL (n = 120) or not (n = 120). Both groups were compared regarding donor cycle parameters and recipient cycle outcome. RESULTS: The…

Malemedicine.medical_specialtymedicine.medical_treatmentFertilization in VitroBiologyGonadotropin-Releasing HormoneAndrologyHuman fertilizationOvulation InductionPregnancymedicineHumansBlastocystProgesteroneRetrospective StudiesGynecologyPregnancyOocyte DonationRehabilitationEmbryo donationObstetrics and GynecologyEmbryo TransferOocytemedicine.diseaseEmbryo transferLuteinizationPregnancy rateBlastocystTreatment Outcomemedicine.anatomical_structureReproductive MedicineOocytesFemaleOvulation inductionHuman Reproduction
researchProduct

Change in kidney volume after kidney transplantation in patients with autosomal polycystic kidney disease

2018

BackgroundThe indication to bilateral nephrectomy in patients with autosomal dominant polycystic kidney scheduled for kidney transplantation is controversial. Indeed, the progressive enlargement of cysts may increase the risk of complications and the need for nephrectomy. However, very few studies investigated the change in kidney volume after kidney transplantation.Material and methodsIn this prospective cohort study, the change in native kidney volume in polycystic patients was evaluated with magnetic resonance imaging. Forty patients were included in the study. Kidney diameters and total kidney volume were evaluated with magnetic resonance imaging in patients who underwent simultaneous n…

Malemedicine.medical_treatment030232 urology & nephrology030204 cardiovascular system & hematologyKidneyPathology and Laboratory MedicineNephrectomyVascular MedicineDiagnostic Radiology0302 clinical medicineChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationPolycystic kidney diseaseMedicineProspective StudiesTomographyKidney transplantationPolycystic Kidney DiseasesKidneyMultidisciplinaryRadiology and ImagingQROrgan SizeMiddle AgedMagnetic Resonance ImagingNephrectomyTreatment Outcomemedicine.anatomical_structureNephrologyMedicineFemaleAnatomymedicine.symptomResearch Articlemedicine.medical_specialtyImaging TechniquesScienceUrologySurgical and Invasive Medical ProceduresHemorrhageNeuroimagingKidney VolumeResearch and Analysis MethodsAsymptomaticUrinary System Procedures03 medical and health sciencesSigns and SymptomsDiagnostic MedicineMedical DialysisHumansTransplantationSurgical Excisionurogenital systembusiness.industryBiology and Life SciencesKidneysRenal SystemOrgan Transplantationmedicine.diseaseKidney TransplantationComputed Axial TomographyTransplantationbusinessFollow-Up StudiesNeuroscienceBilateral NephrectomyPLOS ONE
researchProduct

The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer tre…

2015

Objectives To determine if a re-transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1-high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1-HG/G3 initially treated with bacille Calmette–Gu erin, 935 (38%) had a re-TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re-TUR), group 2 (no muscle, re-TUR), group 3 (muscle, no re-TUR) and group 4 (muscle, re-TUR). Clinical out…

Malemedicine.medical_treatment030232 urology & nephrologySettore MED/24 - Urologia0302 clinical medicineImmunologicRetrospective Studiehigh gradere-TURHazard ratioMiddle Agedmedicine.anatomical_structureAdministration IntravesicalTreatment Outcome030220 oncology & carcinogenesisUrological cancers Radboud Institute for Health Sciences [Radboudumc 15]CohortUrinary Bladder NeoplasmBCG VaccineUrologic Surgical Proceduresbladder cancerFemaleHumanReoperationmedicine.medical_specialtyrecurrenceUrologyUrologyT1G3CystectomyArticleCystectomy03 medical and health sciencesbladder cancer; high grade; progression; re-TUR; recurrence; T1G3; UrologyAdjuvants ImmunologicUrethramedicineHumansAdjuvantsT1G3; bladder cancer; high grade; progression; re-TUR; recurrenceRetrospective StudiesAgedNeoplasm StagingBladder cancerbusiness.industryCancerRetrospective cohort studymedicine.diseaseSurgerybladder cancer; high grade; progression; re-TUR; recurrence; T1G3; Adjuvants Immunologic; Aged; BCG Vaccine; Cystectomy; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Reoperation; Retrospective Studies; Treatment Outcome; Urethra; Urinary Bladder Neoplasms; UrologyUrethraUrinary Bladder NeoplasmsprogressionNeoplasm GradingbusinessBCG vaccine
researchProduct

Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study.

2011

Objectives: Nomograms are statistical models designed to maximize predictive accuracy. We have tested the statistical correlation between the predictions of International Bladder Cancer Nomogram Consortium and the clinical outcomes in a multicenter Italian cohort of patients treated with radical cystectomy (RC) and pelvic lymph-nodes dissection. Methods and materials: Two hundred four patients who underwent RC were selected for multiple variable and then enrolled in the study. Patients were tested by the "online tool" based on the nomogram, then stratified and risk grouped for 5-year predicted disease-free survival (pDFS): low risk (67%-100%), intermediate risk (34%-66%), and high risk grou…

Malemedicine.medical_treatmentKaplan-Meier EstimatePostoperative nomogramNomogramCohort StudiesRetrospective StudieArea under curvePostoperative Periodinvasive bladder cancer; Postoperative nomogramAged 80 and overSettore MED/24 - UROLOGIAinvasive bladder cancerMiddle AgedPrognosisOncologyArea Under CurveUrinary Bladder NeoplasmCohortFemaleHumanCohort studyAdultmedicine.medical_specialtyPrognosiUrologyUrologyCystectomyDisease-Free SurvivalCystectomymedicineHumansAgedNeoplasm StagingRetrospective StudiesCarcinoma Transitional CellBladder cancerbusiness.industryRetrospective cohort studyNomogrammedicine.diseaseRadical cystectomyNomogramsROC CurveUrinary Bladder NeoplasmsCohort StudieNeoplasm GradingPredictionbusinessStatistical correlationUrologic oncology
researchProduct

An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer

2018

PURPOSE: The body mass index (BMI) may be associated with an increased incidence and aggressiveness of urological cancers. In this study, we aimed to evaluate the impact of the BMI on survival in patients with T1G3 non-muscle-invasive bladder cancer (NMIBC). METHODS: A total of 1155 T1G3 NMIBC patients from 13 academic institutions were retrospectively reviewed and patients administered adjuvant intravesical Bacillus Calmette-Guérin (BCG) immunotherapy with maintenance were included. Multivariable Cox regression analysis was performed to identify factors predictive of recurrence and progression. RESULTS: After re-TURBT, 288 patients (27.53%) showed residual high-grade NMIBC, while 867 (82.8…

Malemedicine.medical_treatmentPrognosis.030232 urology & nephrologyComorbidityGastroenterologySettore MED/24 - Urologia0302 clinical medicineBladder cancer; Body mass index; Obesity; PrognosisMedicineBody mass indexAged 80 and overHazard ratioBladder cancerCystoscopyMiddle AgedPrognosisTumor BurdenAdministration IntravesicalEditorialTransitional cell carcinomaChemotherapy Adjuvant030220 oncology & carcinogenesisBCG VaccineDisease ProgressionFemalemedicine.medical_specialtyPrognosiUrologyCystectomyDisease-Free SurvivalCystectomy03 medical and health sciencesAdjuvants ImmunologicInternal medicineHumansObesityMortalityAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesCancer stagingCarcinoma Transitional CellBladder cancer; Body mass index; Obesity; Prognosis; UrologyScience & TechnologyBladder cancerbusiness.industryProportional hazards modelmedicine.diseaseUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisbusinessBody mass index
researchProduct

Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat.

2009

Summary Purpose:  We evaluated the possible additive effect induced by the administration of the anticonvulsant vigabatrin (VGB) and cholecystokinin-8 sulfate (CCK-8S) on an experimental model of partial complex seizures (maximal dentate gyrus activation, MDA). Moreover, the functional involvement of γ-aminobutyric acid (GABA) neurotransmission was tested by iontophoretically administering bicuculline (GABA receptor antagonist) in the dentate gyrus. Methods:  Urethane anesthetized rats were pretreated with VGB (50, 100 or 200 mg/kg, i.p.) or CCK-8S (8 nmol/kg, i.p.) alone or coadministered with VGB (50 mg/kg, i.p.). Dentate gyrus epileptic activity was obtained through the repetitive electr…

Malemedicine.medical_treatmentStimulationConvulsantsNeurotransmissionPharmacologyBicucullineRat Partial epilepsy Vigabatrin Cholecystokinin-8 sulfate ControlVigabatrinDrug Administration ScheduleSincalideVigabatrinEpilepsy Complex PartialmedicineReaction TimeAnimalsRats WistarEvoked PotentialsNootropic AgentsAnalysis of VarianceIontophoresisDose-Response Relationship DrugChemistryDentate gyrusDrug SynergismBicucullineGABA receptor antagonistElectric StimulationRatsDisease Models AnimalAnticonvulsantNeurologyAnesthesiaDentate GyrusAnticonvulsantsDrug Therapy CombinationNeurology (clinical)medicine.drugEpilepsia
researchProduct

Oculoectodermal syndrome: Report of a new case with a broad clinical spectrum

2014

Oculoectodermal syndrome (OMIM 600268) is rare and characterized by aplasia cutis congenita, epibulbar dermoids, and other abnormalities. We report herein on a newly recognized patient with oculoectodermal syndrome, which is the 19th reported patient with OES. The boy aged six years demonstrated a broad clinical spectrum of this condition, including aplasia cutis congenita, epibulbar dermoids, hyperkeratotic papule, mildly enlarged cisterna magna, and an enlarged fluid space in the quadrigeminal cistern, suggesting a cyst. He also manifested anomalies not reported associated with this disorder, including systematized epidermal nevus following Blaschko's lines, hypopigmented skin lesions, an…

Malemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAplasia cutis congenitaHypopigmented skin lesionsEctodermal DysplasiaOculoectodermal syndromeGeneticsmedicineHumansCystGenetics (clinical)Dermoid CystSkinHyperkeratotic papuleHypopigmentationSystematized epidermal nevusbusiness.industryEpibulbar dermoidsBrainmedicine.diseaseMagnetic Resonance ImagingDermatologyEnlarged cisterna magnaPhenotypeChild Preschoolmedicine.symptombusinessAmerican Journal of Medical Genetics Part A
researchProduct